Wilson Sonsini Goodrich & Rosati advised Venatorx on IP matters in the transaction. Melinta Therapeutics LLC (Melinta) and Venatorx Pharmaceuticals, Inc. (Venatorx), announced that they have...
Melinta Therapeutics’ Licensing Agreement with Venatorx Pharmaceuticals
Seal Rock Therapeutics’ Out-Licensing Agreement with GENFIT
Wilson Sonsini Goodrich & Rosati advised Seal Rock on the transaction. Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, has...
Ventyx’s $174 Million IPO
Wilson Sonsini Goodrich & Rosati advised Ventyx on the deal. Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living...
Arena Pharmaceuticals’ Strategic Collaboration with Aristea Therapeutics
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
Aristea’s $63 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
Ventyx Biosciences’ $114 Million Equity Financing
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal. Taylor Wessing advised Oppilan Pharma Limited and Zomagen Biosciences Limited. Ventyx Biosciences, a clinical-stage biotechnology...